[go: up one dir, main page]

AR064133A1 - Moduladores de jnk - Google Patents

Moduladores de jnk

Info

Publication number
AR064133A1
AR064133A1 ARP070105424A ARP070105424A AR064133A1 AR 064133 A1 AR064133 A1 AR 064133A1 AR P070105424 A ARP070105424 A AR P070105424A AR P070105424 A ARP070105424 A AR P070105424A AR 064133 A1 AR064133 A1 AR 064133A1
Authority
AR
Argentina
Prior art keywords
alkyl
nra
halogen
nrac
phenyl
Prior art date
Application number
ARP070105424A
Other languages
English (en)
Inventor
Wylie Solang Palmer
David Michael Goldstein
Leyi Gong
Joan Heather Hogg
Christophe Michoud
Teresa Alejandra Trejo-Martin
James Patrick Dunn
Achyutharao Sidduri
Tania Silva
Parcharee Tivitmahaisoon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39099641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR064133A1 publication Critical patent/AR064133A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a compuestos moduladores de la JNK, (quinasa c-Jun-N-terminal), utiles para artritis reumatoidea, asma, diabetes tipo II, Alzheimer, Parkinson. Reivindicacion 1: Un compuesto de formula (1), en la que X1 es N, N-R3, CHR3, C-R3, u O; X2 es N, NH, N-CH3, CH, CH2, CHCH3 o C-CH3; X3 es N, C o CH, pero X1, X2, y X3 no son todos N al mismo tiempo; X4, X5 con independencia entre sí son C, CH o N; X6 es N o C-R1; en la que por lo menos dos, pero no más de cuatro de X1, X2, X3, X4, X5, y X6 son N; y en la que los enlaces entre X1 y X2, X2 y X3, X3 y X4, X4 y X5, X5 y X1, y X5 y X6 con independencia entre sí pueden ser sencillos o dobles o pueden formar un anillo aromático, con la condicion de que la estructura resultante sea químicamente estable; R es -(ciclohexil)-R2 o -(fenil)-R8, dichos ciclohexilo y fenilo están cada uno de ellos opcionalmente sustituidos por metilo, fluor, cloro o hidroxi; R1 es halogeno, nitro, -CN, -CH2CN, -OH, -NH2, -COOH o Y1R4; Y1 es -O-, -NH- , -S-, -SO-, -SO2-, -NHSO2-, -NHC(O)-, -C(O)NH-, -C(O)O-, o un enlace; R4 es alquilo C1-6, acilo, fenilo o bencilo, cada uno de ellos está sustituido por 0-3 hidroxi o halogeno; n es el numero 0, 1 o 2; R3 H o alquilo C1-6; R2 es H, -OH, -SO2NH2, =O, -CN, o -Y2-Y3-Y4-R5, en los que Y2 es -C(O)-, -C(O)NRa-, -SO2-, -O-, -NH-, o un enlace; Y3 es alquileno C1-6 o un enlace; Y4 es -O-, -NRa-, -S-, -SO2-, -C(O)-, -C(O)NRa-, -NRaC(O)-, -NRaC(O)O-, -NRaC(O)NRa-, -NHSO2-, -SO2-NH-, o un enlace; R5 es alquilo C1-6, cicloalquilo C3-10, heterociclilo, en el que R5 está opcionalmente sustituido por -OH o -NHRa; en el que cada Ra es con independencia H o alquilo C1-6; R8 es H, alquilo C1-6, -OR3, -SO2NH2, -NHSO2R3, -COOR3, -SO2R3, -NH2, -CONRaR3, - NHC(O)R3, -CF3, -NO2, halogeno, o -CN; Z es hidrogeno, halogeno, alquilo C1-12, o NH2; o una sal farmacéuticamente aceptable del mismo.
ARP070105424A 2006-12-08 2007-12-05 Moduladores de jnk AR064133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87362506P 2006-12-08 2006-12-08

Publications (1)

Publication Number Publication Date
AR064133A1 true AR064133A1 (es) 2009-03-11

Family

ID=39099641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105424A AR064133A1 (es) 2006-12-08 2007-12-05 Moduladores de jnk

Country Status (18)

Country Link
US (1) US8399462B2 (es)
EP (1) EP2102194A1 (es)
JP (1) JP5179509B2 (es)
KR (1) KR101152162B1 (es)
CN (1) CN101547917A (es)
AR (1) AR064133A1 (es)
AU (1) AU2007328981B2 (es)
BR (1) BRPI0720003A2 (es)
CA (1) CA2670375A1 (es)
CL (1) CL2007003502A1 (es)
IL (1) IL198543A0 (es)
MX (1) MX2009005508A (es)
NO (1) NO20091942L (es)
PE (1) PE20081507A1 (es)
RU (1) RU2493155C2 (es)
TW (1) TW200831101A (es)
WO (1) WO2008068171A1 (es)
ZA (1) ZA200903495B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679211A (zh) * 2007-06-15 2010-03-24 霍夫曼-拉罗奇有限公司 用于制备3-氨基-戊-1,5-二醇的新方法
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
EP2283009B1 (en) * 2008-05-16 2012-08-29 F. Hoffmann-La Roche AG Inhibitors of jnk
EP2379527A1 (en) * 2008-12-19 2011-10-26 F. Hoffmann-La Roche AG Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation
SG173792A1 (en) 2009-02-24 2011-10-28 Hoffmann La Roche Imidazo [1, 2 -a] pyridines as jnk modulators
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
WO2011018417A1 (en) * 2009-08-10 2011-02-17 F. Hoffmann-La Roche Ag Inhibitors of jnk
NZ599041A (en) * 2009-11-13 2014-05-30 Genosco Kinase inhibitors
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011151358A1 (en) * 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
WO2011151357A1 (en) * 2010-06-04 2011-12-08 F. Hoffmann-La Roche Ag Inhibitors of jnk
US9139590B2 (en) 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
HUE038714T2 (hu) 2011-03-10 2018-11-28 Daiichi Sankyo Co Ltd Dispiropirrolidin származék
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
JP6313312B2 (ja) 2012-10-02 2018-04-18 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 農薬としての複素環化合物
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2964221B1 (en) 2013-03-04 2017-12-06 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
US9809568B2 (en) * 2013-11-14 2017-11-07 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CA2944669A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10954240B2 (en) 2014-09-03 2021-03-23 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
SG11201704685TA (en) * 2014-12-11 2017-07-28 Beta Pharma Inc Substituted 2-anilinopyrimidine derivatives as egfr modulators
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2017133658A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
TW201904577A (zh) 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
EP4155308A4 (en) * 2020-07-14 2024-04-17 Wuhan LL Science and Technology Development Co., Ltd. ROCK INHIBITOR AND PRODUCTION PROCESS AND USE THEREOF
CN113563310B (zh) * 2021-06-25 2022-10-11 浙江工业大学 一种4-(1-甲基吲哚-3-基)嘧啶类衍生物及其应用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114790174B (zh) * 2022-04-14 2023-09-29 淮阴工学院 一种连续合成1h-吲唑类化合物的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US20030004174A9 (en) * 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
CA2398274C (en) * 2000-02-25 2009-09-22 F. Hoffmann-La Roche Ag Adenosine receptor modulators
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
DE60210944T3 (de) * 2001-02-23 2015-07-23 Merck Sharp & Dohme Corp. N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten
WO2002102783A1 (en) * 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1463730B1 (en) * 2001-12-17 2006-04-19 SmithKline Beecham Corporation Pyrazolopyridazine derivatives
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
CN101218241B (zh) * 2005-05-16 2011-02-16 Irm责任有限公司 用作蛋白激酶抑制剂的吡咯并吡啶衍生物
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
MX2009002229A (es) 2006-09-08 2009-03-16 Hoffmann La Roche Benzotriazoles como moduladores de cinasas.
MX2009003456A (es) 2006-10-02 2009-04-14 Irm Llc Compuestos y composiciones como inhibidores de proteina cinasa.
EP2079728B1 (en) 2006-10-10 2013-09-25 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
EP2379527A1 (en) * 2008-12-19 2011-10-26 F. Hoffmann-La Roche AG Pyrimidin- 2 -ylamino derivatives and their use to treat inflammation

Also Published As

Publication number Publication date
JP5179509B2 (ja) 2013-04-10
WO2008068171A9 (en) 2009-07-16
EP2102194A1 (en) 2009-09-23
TW200831101A (en) 2008-08-01
MX2009005508A (es) 2009-06-03
CL2007003502A1 (es) 2008-06-27
BRPI0720003A2 (pt) 2018-09-18
RU2009125672A (ru) 2011-01-20
AU2007328981B2 (en) 2013-07-11
NO20091942L (no) 2009-07-07
CN101547917A (zh) 2009-09-30
PE20081507A1 (es) 2008-11-12
WO2008068171A1 (en) 2008-06-12
RU2493155C2 (ru) 2013-09-20
US20080146565A1 (en) 2008-06-19
KR20090075877A (ko) 2009-07-09
KR101152162B1 (ko) 2012-07-10
AU2007328981A1 (en) 2008-06-12
ZA200903495B (en) 2010-04-28
JP2010511655A (ja) 2010-04-15
US8399462B2 (en) 2013-03-19
CA2670375A1 (en) 2008-06-12
IL198543A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
AR064133A1 (es) Moduladores de jnk
PA8606901A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
DOP2010000192A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
GT200300240A (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
PE20140471A1 (es) Moduladores de la via del complemento y usos de los mismos
UY32146A (es) Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
AR085908A1 (es) DERIVADOS DE 3-BUTIN-2-OL Y DE CARBONITRILO CON ACTIVIDAD INHIBIDORA DE LA QUINASA INDUCTORA DE NF-kB (NIK)
DOP2010000272A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
JP2010132673A5 (es)
PE20141431A1 (es) USO DE COMPUESTOS TIPO ESTROBILURINA PARA COMBATIR HONGOS FITOPATOGENICOS RESISTENTES A INHIBIDORES DE Qo
PE20071311A1 (es) Compuestos 8-azabiciclo[3.2.1]octano como antagonistas del receptor opioide mu
AR080974A1 (es) Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras.
AR044829A1 (es) Derivados de bis-4-cloro fenil pirazinas
AR071385A1 (es) Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia.
UY28915A1 (es) Derivados de tetraazabenzo (e)azuleno y sus análogos
AR079749A2 (es) Derivados de azaindoles heterociclicos inhibidores de quinasas jak-3, aurora a y rock, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades del sistema nervioso central y trastornos inmunologicos y/o alergicos.
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
PE20110805A1 (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso
PE20050036A1 (es) COMPUESTOS DE FENIL-AZA-BENZIMIDAZOL PARA MODULAR LA IgE E INHIBIR LA PROLIFERACION CELULAR
AR049398A1 (es) Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados.
AR111756A1 (es) 4-difluorometilbenzoilamidas de acción herbicida
CL2009000877A1 (es) Compuestos derivados de [tiazolopiridin o tiazolopirazin-2-iloxi fenilamina; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno o afeccion mediado por leucotrieno a4 hidrolasa, tales como alergia, asma, inflamacion, psoriasis, lupus, miastenia gravis, entre otros.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal